Notícias

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.

Companies in The News Are: MA,BMY,MO,REGN

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Bristol-Myers Squibb (BMY) reported second quarter 2026 results that exceeded Wall Street expectations, with revenue and earnings per share ahead of forecasts and management raising full year guidance for both measures. See our latest analysis for Bristol-Myers Squibb. The strong Q2 surprise has come on top of an already solid run for Bristol-Myers Squibb, with a 1-month share price return of 12.57% and a year to date share price return of 21.32%. Over a longer horizon, total shareholder...

Moby summary of Bristol-Myers Squibb Company's Q2 2026 earnings call

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

It notched convincing beats on analyst estimates with its second-quarter performance.

Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that comfortably exceeded Wall Street expectations, driven by continued strength across its growth portfolio. The pharmaceutical company also raised its full-year 2026 financial outlook, sending its shares more than 1% higher in premarket trading on Thursday.

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively tra

Bristol Myers (BMY) delivered earnings and revenue surprises of +28.30% and +11.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates

US stock futures pointed to a higher open on Thursday as investors awaited a key inflation report fo

Investing.com -- Bristol-Myers Squibb shares rose more than 1% in premarket trading Thursday after the drugmaker posted second-quarter results well ahead of expectations and raised its full-year guidance.

By Michael Erman July 30 (Reuters) - Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.

Bristol-Myers Squibb Company will release earnings for its second quarter before the opening bell on Thursday, July 30. Analysts expect the company to report quarterly earnings of $1.60 per share, up from $1.46 per share in the year-ago period. The...

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

Bristol-Myers Squibb stock has delivered a 42.2% return over the past year, while the current checks suggest the shares are not a straightforward bargain or clear premium, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside against a more balanced overall valuation score. The 42.2% one year return signals that a lot more optimism is now reflected in Bristol-Myers Squibb's share price than a year ago. Expanded use of Nvidia AI systems and a new San Diego R&D hub can...

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for.

Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

In recent days, Bristol Myers Squibb has been in focus as analysts updated earnings forecasts and a biotech partner sought approval for its first commercial product to be used alongside BMS’s cancer drug Opdivo. At the same time, commentators have highlighted Bristol Myers Squibb’s role as a dividend-oriented value name with a pipeline viewed as important for offsetting future patent expirations and evolving product sales trends. Building on this, we’ll explore how higher earnings...

Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.